- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01051349
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)
A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Brno, Cechia, 625 00
- Research Site
-
Brno, Cechia, 656 91
- Research Site
-
Hradec Kralove, Cechia, 500 02
- Research Site
-
Prague, Cechia, 100 34
- Research Site
-
Teplice, Cechia, 415 29
- Research Site
-
-
-
-
-
Kazan, Federazione Russa, 420021
- Research Site
-
Krasnoyarsk, Federazione Russa, 660049
- Research Site
-
Moscow, Federazione Russa, 107150
- Research Site
-
Moscow, Federazione Russa, 115682
- Research Site
-
Moscow, Federazione Russa, 6127018
- Research Site
-
Nizhniy Novgorod, Federazione Russa, 603076
- Research Site
-
Novosibirsk, Federazione Russa, 630087
- Research Site
-
Omsk, Federazione Russa, 644033
- Research Site
-
Samara, Federazione Russa, 443095
- Research Site
-
Smolensk, Federazione Russa, 214018
- Research Site
-
St Petersburg, Federazione Russa, 194291
- Research Site
-
Ufa, Federazione Russa, 450005
- Research Site
-
Yaroskavi, Federazione Russa, 150030
- Research Site
-
-
-
-
-
Bayreuth, Germania, 95445
- Research Site
-
Erlangen, Germania, 91054
- Research Site
-
Marburg, Germania, 35043
- Research Site
-
Rostock, Germania, 18147
- Research Site
-
-
-
-
-
Bangalore, India, 560034
- Research Site
-
Hyderabad, India, 500082
- Research Site
-
Kolkata, India, 700068
- Research Site
-
Mumbai, India, 400012
- Research Site
-
Rajasthan, India, 302021
- Research Site
-
-
-
-
-
Bialystok, Polonia, 15-276
- Research Site
-
Bialystok, Polonia, 15-420
- Research Site
-
Gdansk, Polonia, 80-803
- Research Site
-
Katowice, Polonia, 40-749
- Research Site
-
Katowice, Polonia, 40-752
- Research Site
-
Krakow, Polonia, 31-505
- Research Site
-
Lodz, Polonia, 93-121
- Research Site
-
Lublin, Polonia, 20954
- Research Site
-
Warsaw, Polonia, 02-957
- Research Site
-
Warszawa, Polonia, 02-097
- Research Site
-
-
-
-
-
London, Regno Unito, SE59RF
- Research Site
-
Nottingham, Regno Unito, NG72UH
- Research Site
-
Plymouth, Regno Unito, PL68DH
- Research Site
-
Sheffield, Regno Unito, S102JF
- Research Site
-
Stoke-on-Trent, Regno Unito, ST47LN
- Research Site
-
-
-
-
-
Chernivtsi, Ucraina, 58018
- Research Site
-
Dnipropetrovsk, Ucraina, 49027
- Research Site
-
Donetsk, Ucraina, 83003
- Research Site
-
Kharkiv, Ucraina, 61068
- Research Site
-
Kiev, Ucraina, 03110
- Research Site
-
Kiev, Ucraina, 2125
- Research Site
-
Kyiv, Ucraina, 03110
- Research Site
-
Poltava, Ucraina, 36024
- Research Site
-
Zaporizhia, Ucraina, 69035
- Research Site
-
Zaporizhia, Ucraina, 69600
- Research Site
-
-
-
-
-
Budapest, Ungheria, 1083
- Research Site
-
Budapest, Ungheria, 1115
- Research Site
-
Budapest, Ungheria, 1125
- Research Site
-
Budapest, Ungheria, 1076
- Research Site
-
Budapest, Ungheria, 1134
- Research Site
-
Debrecen, Ungheria, 4032
- Research Site
-
Esztergom, Ungheria, 2500
- Research Site
-
Gyor, Ungheria, 9024
- Research Site
-
Kecskemet, Ungheria, 6000
- Research Site
-
Miskolc, Ungheria, 3526
- Research Site
-
Miskolc, Ungheria, 3533
- Research Site
-
Nyiregyhaza, Ungheria, 4400
- Research Site
-
Siofok, Ungheria, 8600
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Main Study Eligibility:
Key Inclusion Criteria:
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- Subjects who have completed 52 weeks in Study 205MS202 (NCT00870740) and were compliant with the 205MS202 protocol in the opinion of the Investigator.
- Women of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment.
Key Exclusion Criteria:
- Subjects with any significant change in their medical status from the previous study that would prelude administration of Daclizumab High Yield Process (DAC HYP) as determined by the Investigator including laboratory tests or a current clinically significant condition that, in the opinion of the Investigator, would have excluded the subject's participation in the 205MS201 (NCT00390221) or 205MS202 (NCT00870740) studies. The Investigator must re-review the subject's medical fitness for participation and must consider any diseases that would preclude treatment.
- Any subject who has permanently discontinued study treatment in Study 205MS202 (NCT00870740) due to an adverse event.
- Current enrollment in any investigational drug study other than Study 205MS202 (NCT00870740).
- Ongoing treatment with any approved or experimental disease-modifying treatment for multiple sclerosis.
For subjects currently taking valproic acid, carbamazepine, lamotrigine, or phenytoin:
- Subjects treated with any of these agents for fewer than 6 months prior to study entry are excluded from study participation unless they discontinue the agent(s) prior to study entry.
- Subjects treated with 2 or more of these agents for more than 6 months prior to study entry are excluded from study participation unless they reduce to ≤1 agent prior to study entry.
- Subjects who have had dose escalations of one of these agents within the 6 months prior to study entry are excluded from study participation unless they revert to a previous dose that had been used for at least 6 months prior to study entry or unless they discontinue the agent prior to study entry
- Subjects who are currently receiving treatment with isoniazid, propylthiouracil, or nimesulide at the time of study entry and are not able to discontinue the agent or change to an alternative medication allowed by the protocol.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: BIIB019
Participants received BIIB019, 150 mg subcutaneous injection every 4 weeks up to Week 288.
|
Administered as specified in the treatment arm.
Altri nomi:
All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Withdrawals Due to AEs
Lasso di tempo: Baseline up to 24 weeks after last dose of treatment (Up to 300 weeks)
|
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
|
Baseline up to 24 weeks after last dose of treatment (Up to 300 weeks)
|
Area Under the Concentration-Time Curve Over the Dosing Interval (AUC0-t) After Dose 4 for Daclizumab
Lasso di tempo: Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions Compared to Baseline
Lasso di tempo: From Baseline through 288 weeks
|
New or newly enlarging T2 hyperintense lesions evaluated by magnetic resonance imaging (MRI) and analyzed by a central reader.
|
From Baseline through 288 weeks
|
Annual Change in Volume of New or Newly Enlarging T2 Hyperintense Lesions Compared to Baseline
Lasso di tempo: From Baseline through 288 weeks
|
New or newly enlarging T2 hyperintense lesions evaluated by MRI and analyzed by a central reader.
|
From Baseline through 288 weeks
|
Number of Participants With Total Number of New Gadolinium-enhancing Lesions
Lasso di tempo: From Baseline through 288 weeks
|
New Gadolinium-enhancing lesions was evaluated by MRI and analyzed by a central reader.
|
From Baseline through 288 weeks
|
Annual Change in Number of T1 Hypointense Lesions
Lasso di tempo: From Baseline through 288 weeks
|
From Baseline through 288 weeks
|
|
Annual Change in Volume of New Gadolinium-Enhancing Lesions
Lasso di tempo: From Baseline through 288 weeks
|
From Baseline through 288 weeks
|
|
Annual Change in Volume of T1 Hypointense Lesions
Lasso di tempo: From Baseline through 288 weeks
|
Volume of T1 hypointense lesions was evaluated by MRI and analyzed by a central reader.
|
From Baseline through 288 weeks
|
Percent Change in Total Brain Volume
Lasso di tempo: From Baseline through 288 weeks
|
To assess brain atrophy, total brain volume was be measured by MRI and analyzed by a central reader.
|
From Baseline through 288 weeks
|
Number of Participants With Antibodies to DAC HYP
Lasso di tempo: Up to Week 288
|
Up to Week 288
|
|
Annualized Relapse Rate (ARR)
Lasso di tempo: Week 288
|
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.
The ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.
Adjusted ARR was reported.
|
Week 288
|
Number of Participants With Sustained Disability Progression for 12 Weeks
Lasso di tempo: Week 48 up to Week 288
|
Sustained disability progression defined by at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from a baseline EDSS ≥1.0 that is sustained for 12 weeks, or at least a 1.5-point increase on the EDSS from a baseline EDSS <1.0 that is sustained for 12 weeks.
The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10, with higher scores indicating more disability.
|
Week 48 up to Week 288
|
Number of Participants With Sustained Disability Progression for 24 Weeks
Lasso di tempo: Week 48 up to Week 288
|
Sustained disability progression defined by at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from a baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from a baseline EDSS <1.0 that is sustained for 24 weeks.
The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10, with higher scores indicating more disability.
|
Week 48 up to Week 288
|
Observed Maximum Concentration (Cmax) After Dose 4 for Daclizumab
Lasso di tempo: Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
|
Time to Reach Maximum Concentration (Tmax) for Daclizumab After Dose 4
Lasso di tempo: Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
|
Observed Minimum Concentration (Cmin) for Daclizumab After Dose 4
Lasso di tempo: Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
Day 90 (Week 12) at predose and 8, 24, 72 and 120 hours post-dose and 7, 10, 14, 21 and 28 days post-dose
|
|
Participant-Reported Pain Visual Analog Scale (VAS) Score
Lasso di tempo: First injection (Day 1) and fourth injection (Day 90) 0 hour, 30 minutes, 60 minutes and 8 hours post-dose
|
The VAS is a 10 cm-long horizontal line labeled with 2 extremes of pain at either end ("0 [no pain]" on the left and "100 [very painful]" on the right).
The participant rates their perceived pain of each injection by placing a vertical mark on the line to indicate the level of pain.
|
First injection (Day 1) and fourth injection (Day 90) 0 hour, 30 minutes, 60 minutes and 8 hours post-dose
|
Summary of Injection Site Assessment Performed by Clinician
Lasso di tempo: First injection (Day 1) and fourth injection (Day 90) 30 minutes; 8, 24, 72, and 120 hours; and 7, 10, and 14 days post-dose
|
Injection site assessment was performed by clinician and are defined as erythema (redness) rated on a 4 point scale ranging from 0-3, where 0=none, 1=mild, 2=moderate and 3=severe; pigmentation changes (skin discoloration other than redness) rated on a 3 point scale from 0-2, where 0=none, 1=hypopigmentation and 2=hyperpigmentation; induration (swelling) rated on a 4 point scale ranging from 0-3, where 0=none, 1=mild, 2=moderate and 3=severe; tenderness to pressure rated on a 4 point scale ranging from 0-3, where 0=none, 1=mild, 2=moderate and 3=severe; and local temperature changes of injection sites rated on a 3 point scale where 0=normal, 1=warm and 1=hot. Only those score categories for which there was at least 1 participant are reported. Here, Injection=Inj, post-dose=PD |
First injection (Day 1) and fourth injection (Day 90) 30 minutes; 8, 24, 72, and 120 hours; and 7, 10, and 14 days post-dose
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T, Robinson RR, Fam S, Smith J, Chalkias S, Giannattasio G, Lima G, Castro-Borrero W. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct;267(10):2851-2864. doi: 10.1007/s00415-020-09835-y. Epub 2020 May 25.
- Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26;16:117. doi: 10.1186/s12883-016-0635-y.
- Gold R, Stefoski D, Selmaj K, Havrdova E, Hurst C, Holman J, Tornesi B, Akella S, McCroskery P. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurol Ther. 2016 Dec;5(2):169-182. doi: 10.1007/s40120-016-0048-2. Epub 2016 Jul 13.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Malattie del sistema nervoso
- Malattie del sistema immunitario
- Malattie autoimmuni demielinizzanti, SNC
- Malattie autoimmuni del sistema nervoso
- Malattie demielinizzanti
- Malattie autoimmuni
- Sclerosi multipla
- Sclerosi
- Sclerosi multipla, recidivante-remittente
- Effetti fisiologici delle droghe
- Agenti immunosoppressivi
- Fattori immunologici
- Daclizumab
Altri numeri di identificazione dello studio
- 205-MS-203
- 2009-015318-23 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su BIIB019 (Daclizumab)
-
BiogenAbbVieTerminatoSclerosi multipla | Sclerosi multipla recidivante-remittenteStati Uniti, Danimarca, Italia, Regno Unito, Cechia, Canada, Ungheria, Spagna, Australia, Israele, Georgia, Serbia, Federazione Russa, Ucraina, India, Polonia, Brasile, Francia, Argentina, Germania, Grecia, Irlanda, Messico, Moldavia... e altro ancora
-
BiogenAbbVieCompletatoSclerosi multipla recidivante-remittenteRepubblica Ceca, Polonia, Federazione Russa, Regno Unito, Ungheria, Ucraina, Germania, India
-
BiogenAbbVieCompletatoSclerosi multipla recidivante-remittenteRepubblica Ceca, Polonia, Federazione Russa, Regno Unito, Ungheria, Ucraina, Germania, India
-
BiogenAbbVieCompletatoSclerosi multipla recidivante-remittenteSvezia, Stati Uniti, Brasile, Repubblica Ceca, Italia, Federazione Russa, Spagna, Regno Unito, Germania, Ucraina, Danimarca, Finlandia, Romania, Canada, Francia, Ungheria, Israele, Svizzera, Serbia, India, Messico, Polonia, Ge... e altro ancora
-
King's College Hospital NHS TrustCompletatoLeucemia/linfoma a cellule T dell'adulto associato a HTLV-I (ATLL)Regno Unito
-
Ekberg, Henrik, M.D.Hoffmann-La Roche; Prof. Philip Halloran, Edmonton, Canada (sponsor); Prof. Yves... e altri collaboratoriCompletato
-
National Cancer Institute (NCI)TerminatoMalattia di Hodgkin | Linfoma di HodgkinStati Uniti
-
National Cancer Institute (NCI)Completato